Phase I Study Evaluating Dose, Safety, and Immune Response of Mosaic Hexavalent Influenza Vaccine FluMos-v2 With or Without ALFQ Adjuvant in Healthy Adults
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-10-23
45
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an experimental flu vaccine called FluMos-v2, with and without an adjuvant named ALFQ, in healthy adults aged 18 to 50 years. The study aims to test the safety, tolerability, and immune response of these vaccines. Participants must have received at least one flu vaccine from the 2020-21 through the 2024-25 seasons and agree not to receive the licensed 2025-26 flu vaccine during the study.
Participants will be divided into groups receiving different doses and combinations of FluMos-v2 and ALFQ. Vaccinations are given as two injections into the upper arm muscle approximately 16 weeks apart. Blood, saliva, and nasal samples will be collected at each visit. An optional procedure called apheresis may be done about two weeks after each vaccination to collect white blood cells.
Participants will attend 12 clinic visits over about 15 months, including physical exams, blood tests, and monitoring for flu symptoms. They will record daily symptoms and temperature for a week after each shot. Safety and immune responses will be assessed throughout, including antibody levels and any side effects. The study spans the 2025-26 flu season with follow-up for up to 68 weeks after the first vaccination.
CONDITIONS
Brief Title
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Research Team
V
VRC Clinic
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
FluMos‑v2 investigational vaccine
Standard seasonal influenza vaccine
What it is
A mosaic hexavalent recombinant influenza vaccine (FluMos‑v2), evaluated in sequential dose groups with and without the ALFQ adjuvant in healthy adults
The current licensed seasonal influenza vaccines used routinely for annual prevention
Primary use
Evaluated for safety, tolerability and immunogenicity as a two‑dose regimen in sequential dose groups
Used for routine annual influenza prevention according to national immunization guidance
How it is given or performed
Administered intramuscularly as two doses (Day 0 and Week 16) in sequential dose cohorts, with or without ALFQ adjuvant
Administered as a single intramuscular dose annually according to routine immunization practice
Evidence status
Clinical evaluation underway; no published results yet
Proven to reduce influenza illness and associated complications in observational and clinical studies
Important limitations
Safety, immunogenicity and optimal dose are not yet established; long‑term protection unknown
Seasonal vaccines vary in effectiveness each year depending on strain match
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 50Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Healthy adults aged 18 to 50 years, inclusive
Received at least one licensed influenza vaccine from the 2020-2021 through the 2024-2025 seasons
In good general health without exclusion conditions
Able and willing to complete informed consent
Available for clinic visits for 68 weeks, including through the 2025-2026 influenza season
Able to provide proof of identity
Physical exam and lab results without significant findings and BMI ≤ 35 within 56 days before enrollment
Agree not to receive the 2025-2026 licensed influenza vaccine during participation
Willing to provide blood and mucosal samples for research
Laboratory values within normal range or approved by Principal Investigator
Negative HIV test
For women of childbearing potential: negative pregnancy test and use of effective birth control from 21 days prior to enrollment through study end
You will not qualify if you...
Women who are breastfeeding or planning pregnancy during the study
Receipt of any licensed influenza vaccine within 6 months prior to enrollment
Planned or required receipt of 2025-2026 licensed influenza vaccine
Live attenuated vaccines within 4 weeks prior to enrollment
Inactivated vaccines within 2 weeks prior to enrollment
mRNA vaccines within 4 weeks prior to enrollment
Receipt of specific prior investigational influenza vaccines
Over 10 days of systemic immunosuppressive or cytotoxic medications within 4 weeks prior or any within 14 days prior to enrollment
Blood products within 16 weeks prior
Use of investigational agents within 4 weeks prior or planned during study
Current allergy immunotherapy unless on maintenance
Current anti-TB treatment
History of serious vaccine reactions, angioedema, uncontrolled asthma, diabetes (except gestational), uncontrolled thyroid disease, recent urticaria, immune-mediated diseases, uncontrolled hypertension, bleeding disorders, active or likely recurrent malignancy, certain seizure disorders, asplenia, Guillain-Barre Syndrome, or other conditions impairing consent or participation
Your Study Journey
Screening
Duration - Up to 4 weeks
Participants are screened for eligibility through physical exams, blood tests, and health history review.
1 visit (in-person)
Vaccination Period
Duration - Approximately 16 weeks
Participants receive two doses of the study vaccine or vaccine plus adjuvant, given 16 weeks apart via injection in the upper arm. They keep symptom diaries and have follow-up calls after each shot.
2 vaccination visits plus follow-up calls
Follow-up and Monitoring
Duration - Up to 48 weeks after last vaccination
Participants attend regular clinic visits for blood, saliva, and nasal sample collection. Flu symptoms prompt additional visits. Optional apheresis may be performed about two weeks after each vaccination to collect white blood cells.
Multiple clinic visits over 15 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
4
Similar Trials
Evaluating Safety, Reactogenicity, and Immune Response of mRNA-1010 Vaccine in Healthy Children Ages 9 to Under 18
Phase I Study Evaluating Dose, Safety, and Immune Response of Mosaic Hexavalent Influenza Vaccine FluMos-v2 With or Without ALFQ Adjuvant in Healthy Adults
Evaluation of a Quadrivalent Influenza HA Stem Vaccine SteMos1 With and Without ALFQ Adjuvant in Healthy Adults for Flu Prevention